TrialJAMA neurology2020

Nilotinib Effects on Safety, Tolerability, and Potential Biomarkers in Parkinson Disease: A Phase 2 Randomized Clinical Trial.

Fernando L Pagan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.